Nothing Special   »   [go: up one dir, main page]

PE20041000A1 - PYRAZOLOPYRIMIDINES AS CYCLINE-DEPENDENT KINASE INHIBITORS - Google Patents

PYRAZOLOPYRIMIDINES AS CYCLINE-DEPENDENT KINASE INHIBITORS

Info

Publication number
PE20041000A1
PE20041000A1 PE2003000900A PE2003000900A PE20041000A1 PE 20041000 A1 PE20041000 A1 PE 20041000A1 PE 2003000900 A PE2003000900 A PE 2003000900A PE 2003000900 A PE2003000900 A PE 2003000900A PE 20041000 A1 PE20041000 A1 PE 20041000A1
Authority
PE
Peru
Prior art keywords
kinase inhibitors
cycline
pyrazolopyrimidines
dependent kinase
alkyl
Prior art date
Application number
PE2003000900A
Other languages
Spanish (es)
Inventor
Ronald J Doll
Viyyoor M Girijavallabhan
Tin-Yau Chan
Kamil Paruch
Chad Knutson
Ray Anthony James
Lawrence W Dillard
Michael P Dwyer
Thierry O Fischmann
Vincent Madison
Vinh D Tran
Haengsoon Park
Zhen Min He
Timothy J Guzi
Carmen S Alvarez
Original Assignee
Schering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Drug Discovery filed Critical Schering Corp
Publication of PE20041000A1 publication Critical patent/PE20041000A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R ES ARILO, SUSTITUIDO O NO; R2 ES ALQUINILALQUILO, CN, ALQUILO, ENTRE OTROS; R3 ES H, HALOGENO, ALQUILO, ENTRE OTROS; R4 ES H, HALO, ALQUILO. SON COMPUESTOS PREFERIDOS: A, B, C, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA SIENDO INHIBIDORES DE CINASA DE PROTEINAS UTILES EN EL TRATAMIENTO DE CANCER, INFLAMACION, ARTRITIS, ENFERMEDADES VIRALES Y ENFERMEDADES NEURODEGENERATIVAS, CARDIOVASCULARES Y FUNGICASREFERS TO A COMPOUND OF FORMULA I WHERE R IS ARYL, SUBSTITUTED OR NOT; R2 IS ALKYLALKYL, CN, ALKYL, AMONG OTHERS; R3 IS H, HALOGEN, ALKYL, AMONG OTHERS; R4 IS H, HALO, RENT. THE PREFERRED COMPOUNDS ARE: A, B, C, AMONG OTHERS. ALSO REFERS TO A PHARMACEUTICAL COMPOSITION BEING USEFUL KINASE INHIBITORS OF PROTEINS IN THE TREATMENT OF CANCER, INFLAMMATION, ARTHRITIS, VIRAL DISEASES AND NEURODEGENERATIVE, CARDIOVASCULAR AND FUNGIC DISEASES

PE2003000900A 2002-09-04 2003-09-04 PYRAZOLOPYRIMIDINES AS CYCLINE-DEPENDENT KINASE INHIBITORS PE20041000A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40802902P 2002-09-04 2002-09-04

Publications (1)

Publication Number Publication Date
PE20041000A1 true PE20041000A1 (en) 2004-12-29

Family

ID=32030632

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000900A PE20041000A1 (en) 2002-09-04 2003-09-04 PYRAZOLOPYRIMIDINES AS CYCLINE-DEPENDENT KINASE INHIBITORS

Country Status (19)

Country Link
US (2) US7067661B2 (en)
EP (1) EP1534712B1 (en)
JP (2) JP4790265B2 (en)
KR (1) KR20050033659A (en)
CN (1) CN1701073B (en)
AR (1) AR041133A1 (en)
AT (1) ATE362474T1 (en)
AU (1) AU2003298571B2 (en)
CA (1) CA2497544C (en)
DE (1) DE60313872T2 (en)
ES (1) ES2283868T3 (en)
HK (1) HK1071572A1 (en)
MX (1) MXPA05002572A (en)
MY (2) MY145332A (en)
NZ (1) NZ539161A (en)
PE (1) PE20041000A1 (en)
TW (1) TWI329645B (en)
WO (1) WO2004026229A2 (en)
ZA (1) ZA200501846B (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1506203T3 (en) 2002-08-23 2007-05-14 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereof, analogs thereof and uses thereof
MY145332A (en) * 2002-09-04 2012-01-31 Schering Corp Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7601724B2 (en) * 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
WO2004076458A1 (en) * 2003-02-28 2004-09-10 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JPWO2005035516A1 (en) * 2003-10-10 2006-12-21 小野薬品工業株式会社 Novel fused heterocyclic compounds and uses thereof
WO2005112936A1 (en) * 2004-05-14 2005-12-01 The Regents Of The University Of Michigan Compositions and methods relating to protein kinase inhibitors
JP5334414B2 (en) * 2004-09-06 2013-11-06 バイエル インテレクチュアル プロパティー ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel pyrazolopyrimidine
FR2876582B1 (en) * 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse USE OF PYRROLO-PYRAZINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS
ATE433454T1 (en) * 2004-12-21 2009-06-15 Schering Corp PYRAZOLOÄ1,5-AÜPYRIMIDINES AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
ATE478852T1 (en) 2005-09-09 2010-09-15 Schering Corp NEW 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLOÄ1,5-AÜPYRIDINES, PYRAZOLOÄ1,5-CÜPYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZOÄ1,2- AÜPYRIDINES, AND IMIDAZOÄ1,5-AÜPYRAZINE COMPOUNDS AS INHIBITORS OF CYCLIN-DEPENDENT KINASE
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007118844A1 (en) * 2006-04-13 2007-10-25 Basf Se Substituted pyrazolopyrimidines, process for their preparation and their use for controlling harmful fungi and compositions comprising them
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
CN101495481A (en) * 2006-05-22 2009-07-29 先灵公司 Pyrazolo [1, 5-alpha] pyrimidines as CDK inhibitors
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101547892B (en) * 2006-12-05 2014-08-20 艾尼纳制药公司 Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates thereof
CA2720944C (en) * 2008-04-07 2012-12-18 Irm Llc Compounds and compositions as kinase inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011028638A1 (en) 2009-09-04 2011-03-10 Schering Corporation Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
PL2509602T3 (en) * 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2012149157A2 (en) * 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP6106685B2 (en) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitors of C-JUN-N-terminal kinase (JNK)
KR20140123104A (en) 2012-02-17 2014-10-21 밀레니엄 파머슈티컬스 인코퍼레이티드 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN102633803A (en) * 2012-05-03 2012-08-15 盛世泰科生物医药技术(苏州)有限公司 Synthetic method of 5,7-dichloro pyrazole [1,5-a] pyrimidine
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10392389B2 (en) 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
US9278973B2 (en) 2012-10-25 2016-03-08 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
TR201807740T4 (en) 2012-12-07 2018-06-21 Vertex Pharma 2-amino-6-fluoro-n- (5-fluoro-4- (4- (4- (oxetan-3-yl) piperazine-1-carbonyl) piperidin-1-yl) pyridine-3- as an ATR kinase inhibitor yl) pyrazolo [1,5alf a] pyrimidine-3-carboxamide.
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2015002994A2 (en) 2013-07-02 2015-01-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
SG11201604519PA (en) 2013-12-06 2016-07-28 Vertex Pharma 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
AU2014372638A1 (en) 2013-12-23 2016-06-16 Norgine B.V. Compounds useful as CCR9 modulators
BR112016016798B1 (en) * 2014-01-22 2022-06-28 Curovir Ab COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
RU2719583C2 (en) 2014-06-05 2020-04-21 Вертекс Фармасьютикалз Инкорпорейтед Radiolabelled 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]-pyrazolo [1, 5-a] pyrimidine-3-carboxamide derivatives used as atr kinase inhibitor, preparations based thereon compounds and various solid forms thereof
LT3157566T (en) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
WO2016004136A1 (en) 2014-07-01 2016-01-07 Duffey Matthew O Heteroaryl compounds useful as inhibitors of sumo activating enzyme
WO2016015605A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
RU2768621C1 (en) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Method of treating cancer using a combination of dna damaging agents and atr inhibitors
MX2018006250A (en) 2015-11-18 2018-09-05 Genzyme Corp Biomarker of polycystic kidney disease and uses thereof.
TWI703149B (en) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 Compounds useful for inhibiting cdk7
JP7179161B2 (en) 2018-09-10 2022-11-28 イーライ リリー アンド カンパニー Pyrazolo[1,5-A]pyrimidine-3-carboxamide derivatives useful for treating psoriasis and systemic lupus erythematosus
EP3873911A4 (en) 2018-10-30 2022-06-22 Kronos Bio, Inc. Compounds, compositions, and methods for modulating cdk9 activity
TWI800696B (en) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
TWI810520B (en) 2020-02-12 2023-08-01 美商美國禮來大藥廠 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide compounds
CN116396298A (en) * 2023-06-06 2023-07-07 四川维亚本苑生物科技有限公司 Intermediate XII of CDK bond-1 and preparation method of CDK bond-1

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US626096A (en) * 1899-05-30 Dust-pan
JPS4116288Y1 (en) 1964-11-07 1966-07-28
JPS6157587A (en) 1984-08-29 1986-03-24 Shionogi & Co Ltd Condensed heterocyclic derivative and antiulcerative
JP2585462B2 (en) * 1989-10-25 1997-02-26 株式会社大塚製薬工場 Pyrazolo [1,5-a] pyrimidine derivatives
JP2811020B2 (en) 1990-04-17 1998-10-15 日本特殊陶業株式会社 Joint of ceramic and steel and method of manufacturing the same
KR100191774B1 (en) * 1991-04-22 1999-06-15 오스카 아끼히꼬 Pyrazolo(1,5-alpha)pyrimidine derivatives and anti-inflammatory agent containing them
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0714898B1 (en) 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6190131B1 (en) * 1999-08-31 2001-02-20 General Electric Co. Non-integral balanced coverplate and coverplate centering slot for a turbine
FR2805160B1 (en) 2000-02-23 2002-04-05 Oreal COMPOSITIONS FOR OXIDATION DYEING OF KERATINIC FIBERS COMPRISING N (2-HYDROXYBENZENE) -CARBRAMATE OR N- (2-HYDROXYBENZENE) -UREA AND PYRAZOLOPYRIMIDINE, AND DYEING METHODS
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
FR2817469B1 (en) 2000-12-04 2003-04-18 Oreal COLORING COMPOSITION, PROCESS FOR OBTAINING AND USE FOR COLORING KERATINIC FIBERS
EP1345941A1 (en) 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors
JP2004528295A (en) 2001-01-30 2004-09-16 サイトピア ピーティワイ リミテッド Kinase inhibition method
BR0309475A (en) 2002-04-23 2005-03-01 Shionogi & Co Pyrazolo [1,5-a] pyrimidine derivatives and nad (p) h oxidase inhibitors containing them
DE10223917A1 (en) 2002-05-29 2003-12-11 Bayer Cropscience Ag New 7-amino-6-aryl-pyrazolo-(1,5-a)-pyrimidine derivatives, useful as pesticides, e.g. insecticides, acaricides, nematocides, bactericides or especially fungicides for protection of plants or materials
US7078525B2 (en) * 2002-09-04 2006-07-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY145332A (en) * 2002-09-04 2012-01-31 Schering Corp Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
JP4790265B2 (en) 2011-10-12
MY137843A (en) 2009-03-31
MXPA05002572A (en) 2005-09-08
ZA200501846B (en) 2005-09-12
KR20050033659A (en) 2005-04-12
AR041133A1 (en) 2005-05-04
AU2003298571A1 (en) 2004-04-08
NZ539161A (en) 2006-05-26
HK1071572A1 (en) 2005-07-22
CN1701073B (en) 2011-06-22
TW200413376A (en) 2004-08-01
EP1534712A2 (en) 2005-06-01
WO2004026229A3 (en) 2004-06-17
JP2010180235A (en) 2010-08-19
MY145332A (en) 2012-01-31
TWI329645B (en) 2010-09-01
CN1701073A (en) 2005-11-23
US20060178371A1 (en) 2006-08-10
DE60313872D1 (en) 2007-06-28
ATE362474T1 (en) 2007-06-15
US20040106624A1 (en) 2004-06-03
US7067661B2 (en) 2006-06-27
DE60313872T2 (en) 2008-01-17
CA2497544A1 (en) 2004-04-01
US7514442B2 (en) 2009-04-07
ES2283868T3 (en) 2007-11-01
EP1534712B1 (en) 2007-05-16
CA2497544C (en) 2010-11-02
WO2004026229A2 (en) 2004-04-01
AU2003298571B2 (en) 2006-10-19
JP2006502184A (en) 2006-01-19

Similar Documents

Publication Publication Date Title
PE20041000A1 (en) PYRAZOLOPYRIMIDINES AS CYCLINE-DEPENDENT KINASE INHIBITORS
PE20041076A1 (en) NEW PYRAZOLOPYRIMIDINES AS CYCLINE-DEPENDENT KINASE INHIBITORS
PE20040999A1 (en) NEW PYRAZOLOPYRIMIDINES AS INHIBITORS OF CYCLINE-DEPENDENT KINASES
PE20040998A1 (en) NEW PYRAZOLOPYRIMIDINES AS INHIBITORS OF CYCLINE-DEPENDENT KINASES
PE20070543A1 (en) PYRAZOLOPYRIMIDINES AS PROTEIN KINAS INHIBITORS
CY1109906T1 (en) COPPER C3-KYANO PRODUCER
PE20080931A1 (en) IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS
EA200400971A1 (en) Fluorine-substituted cycloalkanoylindoles, compositions containing such compounds, and methods of treatment
EA200501009A1 (en) SUBSTITUTED PYRROPYRAZOLE DERIVATIVES AS KINASE INHIBITORS
EA200600317A1 (en) DERIVATIVES OF OMEGA-CARBOXYaryldiphenylmoleum (OPTIONS), PHARMACEUTICAL COMPOSITION (OPTIONS) AND METHOD OF TREATMENT AND PREVENTION OF DISEASES AND STATES WITH THEIR USE (OPTIONS)
DE60328010D1 (en) HETEROCYCLIC COMPOUNDS
ATE484508T1 (en) FURYL COMPOUNDS
BRPI0413452A (en) compound, pharmaceutical composition, kit, article of manufacture, and methods of inhibiting dpp-iv, therapeutic, and treating a disease state, cancer, autoimmune disorders, a condition and HIV infection
CY1108292T1 (en) DMXAA ANTI-CANCER CONTAINER
BRPI0510177B8 (en) compound, pharmaceutical composition and use thereof
PE20070805A1 (en) IMIDAZOPYRAZINES AS PROTEINQUINASE INHIBITORS
DE50310516D1 (en) Fredericamycin DERIVATIVES
DE60315146D1 (en) HETEROARYLSUBSTITUTED BIPHENYL DERIVATIVES AS INHIBITORS OF P38 KINASE
DE60314623D1 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES
DE60333746D1 (en) thienyl compounds
ECSP045469A (en) THE USE OF REPLACED CYANOPIRROLIDINS AND COMBINATION PREPARATIONS CONTAINING THEM TO TREAT HYPERLIPIDEMIA AND ASSOCIATED DISEASES
EA200600605A1 (en) REJUVENATED PENTANOLS, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS ANTI-INFLAMMATORY MEANS
DE602005027728D1 (en) Benzodiazepine derivatives as ROCK kinase inhibitors
EA200401319A1 (en) NEW HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR USE IN MEDICINE
NO20053562L (en) Novel aminobenzophenone compounds

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed